| Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis … C Thiede, C Steudel, B Mohr, M Schaich, U Schäkel, U Platzbecker, ... Blood, The Journal of the American Society of Hematology 99 (12), 4326-4335, 2002 | 2090 | 2002 |
| Mesenchymal stem cells can be differentiated into endothelial cells in vitro J Oswald, S Boxberger, B Jørgensen, S Feldmann, G Ehninger, ... Stem cells 22 (3), 377-384, 2004 | 1803 | 2004 |
| Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open … J Finke, WA Bethge, C Schmoor, HD Ottinger, M Stelljes, AR Zander, ... The lancet oncology 10 (9), 855-864, 2009 | 754 | 2009 |
| Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk … C Schmid, M Labopin, A Nagler, M Bornhäuser, J Finke, A Fassas, ... Journal of clinical oncology 25 (31), 4938-4945, 2007 | 527 | 2007 |
| Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party … N Kröger, E Holler, G Kobbe, M Bornhäuser, R Schwerdtfeger, ... Blood, The Journal of the American Society of Hematology 114 (26), 5264-5270, 2009 | 455 | 2009 |
| Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) B Wassmann, H Pfeifer, N Goekbuget, DW Beelen, J Beck, M Stelljes, ... Blood 108 (5), 1469-1477, 2006 | 449 | 2006 |
| The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach JJ Cornelissen, A Gratwohl, RF Schlenk, J Sierra, M Bornhaeuser, ... Nature reviews Clinical oncology 9 (10), 579-590, 2012 | 442 | 2012 |
| Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, ... Leukemia 26 (3), 381-389, 2012 | 420 | 2012 |
| Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 … C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ... The lancet oncology 16 (16), 1691-1699, 2015 | 410 | 2015 |
| Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research S Arai, M Arora, T Wang, SR Spellman, W He, DR Couriel, ... Biology of Blood and Marrow Transplantation 21 (2), 266-274, 2015 | 381 | 2015 |
| Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation RF Chemaly, AJ Ullmann, S Stoelben, MP Richard, M Bornhäuser, ... New England Journal of Medicine 370 (19), 1781-1789, 2014 | 372 | 2014 |
| Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium M Von Bonin, F Stölzel, A Goedecke, K Richter, N Wuschek, K Hölig, ... Bone marrow transplantation 43 (3), 245-251, 2009 | 371 | 2009 |
| Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection C Thiede, M Florek, M Bornhäuser, M Ritter, B Mohr, C Brendel, ... Bone Marrow Transplantation 23 (10), 1055-1060, 1999 | 340 | 1999 |
| Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia … J Donadieu, T Leblanc, BB Meunier, M Barkaoui, O Fenneteau, ... haematologica 90 (1), 45-53, 2005 | 331 | 2005 |
| Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation … A Burchert, G Bug, LV Fritz, J Finke, M Stelljes, C Röllig, E Wollmer, ... Journal of Clinical Oncology 38 (26), 2993-3002, 2020 | 329 | 2020 |
| Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti–T-cell globulin ATG-Fresenius G Socié, C Schmoor, WA Bethge, HD Ottinger, M Stelljes, AR Zander, ... Blood, The Journal of the American Society of Hematology 117 (23), 6375-6382, 2011 | 319 | 2011 |
| Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis J Schetelig, A van Biezen, R Brand, D Caballero, R Martino, M Itala, ... Journal of Clinical Oncology 26 (31), 5094-5100, 2008 | 319 | 2008 |
| Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD K Rieger, C Loddenkemper, J Maul, T Fietz, D Wolff, H Terpe, B Steiner, ... Blood 107 (4), 1717-1723, 2006 | 315 | 2006 |
| Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting … C Röllig, M Bornhäuser, C Thiede, F Taube, M Kramer, B Mohr, W Aulitzky, ... Journal of clinical oncology 29 (20), 2758-2765, 2011 | 304 | 2011 |
| Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia A Ehninger, M Kramer, C Röllig, C Thiede, M Bornhäuser, M Von Bonin, ... Blood cancer journal 4 (6), e218-e218, 2014 | 301 | 2014 |
Christian ThiedeProfessor of Molecular Hematology, University of Technics DresdenVerified email at uniklinikum-dresden.de
